BR100 Increased By (1.42%)
BR30 Increased By (1.24%)
KSE100 Increased By (1.02%)
KSE30 Increased By (1.18%)
AGHA 8.06 Increased By ▲ 0.05 (0.62%)
BECO 5.27 Increased By ▲ 0.09 (1.74%)
BML 59.31 Decreased By ▼ -1.61 (-2.64%)
BOP 33.78 Increased By ▲ 0.73 (2.21%)
CNERGY 9.60 Decreased By ▼ -0.08 (-0.83%)
CSIL 5.43 Increased By ▲ 0.04 (0.74%)
FCCL 51.84 Increased By ▲ 0.93 (1.83%)
FFL 16.66 Increased By ▲ 0.10 (0.6%)
FNEL 1.22 Increased By ▲ 0.02 (1.67%)
KEL 7.44 Decreased By ▼ -0.08 (-1.06%)
KOSM 5.58 Increased By ▲ 0.11 (2.01%)
LOTCHEM 30.58 Increased By ▲ 0.24 (0.79%)
MLCF 95.78 Increased By ▲ 2.46 (2.64%)
NBP 205.30 Increased By ▲ 9.47 (4.84%)
NCPL 55.11 Increased By ▲ 1.29 (2.4%)
NPL 64.80 Increased By ▲ 1.87 (2.97%)
OGDC 320.70 Increased By ▲ 1.20 (0.38%)
PACE 10.54 Increased By ▲ 0.13 (1.25%)
PAEL 41.40 Increased By ▲ 0.34 (0.83%)
PIBTL 16.70 Increased By ▲ 0.25 (1.52%)
PPL 223.49 Increased By ▲ 0.91 (0.41%)
PRL 41.55 Decreased By ▼ -0.50 (-1.19%)
PTC 68.20 Increased By ▲ 1.09 (1.62%)
SSGC 28.50 Increased By ▲ 0.12 (0.42%)
TBL 10.01 Increased By ▲ 0.18 (1.83%)
TELE 8.71 Increased By ▲ 0.08 (0.93%)
TPL 16.60 Increased By ▲ 0.95 (6.07%)
TPLP 12.13 Increased By ▲ 1.10 (9.97%)
TREET 22.85 No Change ▼ 0.00 (0%)
TRG 57.70 Decreased By ▼ -1.11 (-1.89%)

KARACHI: Ferozsons Laboratories Limited is exploring a potential acquisition of Barrett Hodgson Pakistan Pvt Limited, a pharmaceutical company, in collaboration with a consortium of leading Pakistani business groups.

This development follows a board meeting of Ferozsons held last week. During the meeting the company's Board of Directors reviewed the proposal, recommended by the Investment Committee.

The Board of Directors has authorized Chief Executive Officers and Chief Financial Officers to perform the due diligence, appoint advisor, sign all the documents in this respect and to do all other acts including giving bid money, security; etc., in connection with the potential acquisition.

The notice further said that the final purchase and equity investment will be approved by Board of Directors based on the outcomes of due diligence and other parameters, including relevant approvals.

Analysts say that the proposed acquisition is expected to have significant implications for Ferozsons Laboratories Limited, potentially expanding its market presence, product portfolio, and capabilities in the pharmaceutical sector.

Copyright Business Recorder, 2025

Comments

Comments are closed for this article.